Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOR-101 in Healthy Participants and Participants With Moderate-to-Severe Atopic Dermatitis
NCT07904689Phase 1Not yet recruiting
- Sponsor
- North Immunology
- Start
- Nov 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NOR-101 in atopic dermatitis (AD) (6 arms), sponsored by North Immunology. Primary endpoints: Number of participants with adverse events at 29 months, Number of participants with clinically significant vital sign abnormalities at 20 months and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
NOR-101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07904689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904689.